Our client has developed a novel diagnostic approach using DNA nanorobots to target specific biomarkers present in blood samples (such as DNA and RNA). The Company has recently closed a successful funding round and is now well-positioned to seek to exploit its technology to the next level. The candidate will report to the Chair and Board of Directors and direct and develop company strategy in conjunction with the 2 founders, and the existing CEO who will be stepping back to be the CSO and the COO.
The candidate will need to be experienced in handling all elements of developing a commercial strategy, brokering successful joint ventures and collaborations, and bringing innovative products to market ideally in both the research and clinical diagnostics arenas.
This is an outstanding opportunity to lead an innovative organisation within a highly acclaimed area of creative new leading-edge technology. The role will suit a driven, creative, entrepreneurial, and even disruptive thinker; a proven Executive Officer who is Entrepreneurial in outlook, aligned with investor objectives, and who has a track record of successfully building commercial value from novel technology.
The CEO must have a solid demonstrative track record on managing the financial side of the business on a day-to-day basis
The role requires a degree level qualification or a higher degree in Life Sciences or equivalent would be helpful; The role holder must understand the science sufficiently to sell and talk to prospective customers, and expertise gained within more than one Biotech/MedTech/Pharma Company. Previous positions at CEO/COO or Senior Level Executive with the personal credibility to make an early impact is required. They ideally will have developed and grown a platform technology (related to DNA/RNA/genetics/genomics). It is essential that the role holder must have established successful relationships with early-stage investors and institutions; Be able to raise funds (dilutive and non-dilutive) – demonstrated by leading at least one successful series A round.